Subsidiary of Lianhe Pharmaceutical (600513.SH) obtained registration certificate for saxagliptin metformin sustained-release tablets

Zhicheng Financial APP News, Lianhuan Pharmaceutical (600513.SH) announced that its controlling subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Dapagliflozin Metformin Sustained-Release Tablets (I/II/III). Dapagliflozin Metformin Sustained-Release Tablets (I/II/III), when used in conjunction with dietary control and exercise, are suitable for improving blood sugar control in adult patients with type 2 diabetes who are already undergoing treatment with Dapagliflozin and Metformin Hydrochloride. This drug is classified as a Category 4 chemical drug for application, and is considered to have passed the generic drug quality and efficacy consistency evaluation.